Shares of Australian biotechnology company Immutep Ltd experienced a sharp rally Wednesday after the U.S. Food and Drug Administration granted Orphan Drug Designation for the company’s candidate treatment, eftilagimod alfa, aimed at soft tissue sarcoma.
On the Australian Securities Exchange, Immutep (ASX: IMM) stock rose 101.3% to A$0.079 following the announcement.
The company said the FDA award applies to eftilagimod alfa for the treatment of soft tissue sarcoma, which Immutep described as a rare cancer with unmet clinical need. The designation from the FDA is grounded in data from a phase 2 trial of eftilagimod alfa, and Immutep noted that the phase 2 study had met its primary endpoint.
Orphan Drug Designation can convey a range of regulatory and commercial advantages. Immutep highlighted that benefits may include greater regulatory support, potential exemptions from certain taxes and fees, and, if the product is approved, up to seven years of market exclusivity in the U.S.
The FDA’s determination follows a period of reassessment at Immutep. The company previously announced in early-March that it had halted a key phase 3 trial of eftilagimod alfa and launched a comprehensive review and analysis regarding any future clinical trials for the treatment.
Context on third-party evaluations referenced in material accompanying the announcement
Separately included in the public material was a reference to an investment screening tool that evaluates individual stocks. That tool reportedly assesses ICCC and thousands of other companies each month using more than 100 financial metrics and leverages artificial intelligence to identify candidates based on fundamentals, momentum, and valuation. The material cited past examples of notable winners identified by the tool, including Super Micro Computer at +185% and AppLovin at +157%.
Those references were presented as part of broader investor-oriented content and do not alter the regulatory facts surrounding Immutep’s Orphan Drug Designation announcement.
Immutep’s stock response reflects investor reaction to the FDA designation and the potential regulatory and commercial incentives it brings, while the company continues to evaluate the path forward for further clinical development of eftilagimod alfa.